DnB Asset Management
SWTX

DnB Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

DnB Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,444
Closed -$461K – 771
2025
Q1 		$461K Sell
10,444
-1,431
-12% -$65.9K ﹤0.01% 662
2024
Q4 		$429K Sell
11,875
-529
-4% -$18.5K ﹤0.01% 671
2024
Q3 		$397K Buy
12,404
+1,002
+9% +$37.4K ﹤0.01% 667
2024
Q2 		$429K Buy
11,402
+1,617
+17% +$68.1K ﹤0.01% 661
2024
Q1 		$482K Sell
9,785
-2,225
-19% -$103K ﹤0.01% 654
2023
Q4 		$438K Buy
12,010
+24
+0.2% +$626 ﹤0.01% 631
2023
Q3 		$277K Sell
11,986
-2,825
-19% -$77.3K ﹤0.01% 653
2023
Q2 		$388K Buy
14,811
+4,568
+45% +$120K ﹤0.01% 643
2023
Q1 		$264K Buy
10,243
+52
+0.5% +$1.52K ﹤0.01% 642
2022
Q4 		$265K Buy
+10,191
New +$251K ﹤0.01% 630

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

DnB Asset Management's SWTX Position: Q2 2025 in Review

DnB Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 10,444 shares — an estimated $461K sold.

DnB Asset Management first reported a position in SWTX in Q4 2022 and held it in 10 quarters. The position peaked at $482K in Q1 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • DnB Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • DnB Asset Management sold 10,444 SpringWorks Therapeutics shares in Q2 2025, an estimated $461K.
  • DnB Asset Management first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 10 quarters.
  • DnB Asset Management's SpringWorks Therapeutics position peaked at $482K in Q1 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on DnB Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.